Ten of these patients, seven on ALC and three on placebo, did not complete the study because of consent withdrawal (n = 5), loss to follow-up (n = 3), an adverse event (n = 1), and protocol violation (n = 1) (Fig
Neither fact guarantees your result, and anyone promising a number on the scale is overselling
A subsample of EVs was diluted 1:1000 in sterile PBS to a final volume of 1 mL
While safety within the phase 3 program is sufficient for marketing authorization (although the risk of cardiovascular events should not exceed a hazard ratio of 1.8 according to a guidance document that was released by the FDA at that time), it is the post-marketing phase in which rare adverse events and any other potential safety risks are identified or resolved
Blood work tracking HbA1c, fasting glucose, and lipid panels shows metabolic improvements